Unknown

Dataset Information

ROS as a novel indicator to predict anticancer drug efficacy.


ABSTRACT:

Background

Mitochondria are considered a primary intracellular site of reactive oxygen species (ROS) generation. Generally, cancer cells with mitochondrial genetic abnormalities (copy number change and mutations) have escalated ROS levels compared to normal cells. Since high levels of ROS can trigger apoptosis, treating cancer cells with low doses of mitochondria-targeting / ROS-stimulating agents may offer cancer-specific therapy. This study aimed to investigate how baseline ROS levels might influence cancer cells' response to ROS-stimulating therapy.

Methods

Four cancer and one normal cell lines were treated with a conventional drug (cisplatin) and a mitochondria-targeting agent (dequalinium chloride hydrate) separately and jointly. Cell viability was assessed and drug com

SUBMITTER: Zaidieh T 

PROVIDER: S-EPMC6916036 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature